J&J's LOPERAMID Rx-TO-OTC SWITCH SHOULD CAPTURE "SIGNIFICANT" SHARE OF $80 MIL. OTC MARKET; McNEIL PRODUCT IS FORECAST AS NEXT SWITCH BY SRI REPORT

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".